首页> 外文期刊>Scandinavian journal of urology >Grading of urothelial carcinoma of the upper urinary tract according to the World Health Organization/International Society of Urological Pathology classification from 2004 is a valuable tool when considering whether a patient is suitable for endoscopic treatment
【24h】

Grading of urothelial carcinoma of the upper urinary tract according to the World Health Organization/International Society of Urological Pathology classification from 2004 is a valuable tool when considering whether a patient is suitable for endoscopic treatment

机译:自2004年起根据世界卫生组织/国际泌尿外科病理学学会分类对上尿路尿路上皮癌进行分级是考虑患者是否适合内镜治疗的有价值的工具

获取原文
获取原文并翻译 | 示例
           

摘要

Objective The aim of this study was to analyse the results regarding survival, recurrence and kidney preservation after endoscopic treatment for upper urinary tract urothelial carcinoma (UTUC) in a Norwegian hospital during the period from 2001 to 2012, and compare them with results reported in the literature. A further aim was to re-examine all initial histopathological specimens, and stratify primary results according to the World Health Organization/International Society of Urological Pathology grading system of urothelial carcinoma from 2004. Materials and methods Forty-three patients were treated endoscopically with curative intent for UTUC during 2001-2012. Of these, 28 patients were candidates for nephroureterectomy (CNU) with an elective indication, while 15 were non-candidates for nephroureterectomy (NCNU). Analyses were performed separately for the CNU and NCNU groups. Results In the CNU group, the 5 year overall and disease-specific survival (OS and DSS) were 71% and 94%, respectively. In the NCNU group, the OS and DSS were 25% and 41%, respectively. Histopathological verification was available in 40 patients (93%), and re-examination showed 27 low-grade and 13 high-grade tumours. In patients with a low-grade tumour, the OS and DSS were 75% and 96%, respectively. In patients with a high-grade tumour, the OS and DSS were 23% and 39%, respectively. The 5 year kidney protection rate was 51% in the CNU group. The 5 year recurrence-free survival was 72%. Conclusions The endoscopic treatment of UTUC is feasible and safe in histopathologically verified low-grade tumours. The endoscopic treatment of high-grade tumours has poor results, and must be reserved for patients where nephroureterectomy is truly contraindicated.
机译:目的本研究旨在分析2001年至2012年间在挪威医院内镜治疗上尿路尿路上皮癌(UTUC)后的生存,复发和肾脏保存的结果,并将其与文学。另一个目标是重新检查所有最初的组织病理学标本,并根据2004年世界卫生组织/国际泌尿外科病理学协会泌尿上皮癌分级系统对主要结果进行分层。材料和方法对43例患者进行了内镜治疗在2001年至2012年期间为UTUC。在这些患者中,有28例是有选择适应症的肾结直肠切除术(CNU)候选者,而有15例是非肾结石切除术(NCNU)的候选者。对CNU和NCNU组分别进行了分析。结果CNU组的5年总生存率和疾病特异性生存率(OS和DSS)分别为71%和94%。在NCNU组中,OS和DSS分别为25%和41%。 40例患者(93%)可进行组织病理学检查,再次检查显示27例低度和13例高度肿瘤。在低度肿瘤患者中,OS和DSS分别为75%和96%。在患有高级别肿瘤的患者中,OS和DSS分别为23%和39%。 CNU组的5年肾脏保护率为51%。 5年无复发生存率为72%。结论UTUC内镜治疗在组织病理学证实的低度恶性肿瘤中是可行且安全的。内镜治疗高级肿瘤效果差,必须保留给真正禁止肾切除术的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号